Table 1.
Patient Demographics
| Patient Demographics | (n = 20) |
|---|---|
| Age, mean (SD, range) | 59.50 (15.27, 21–81) |
| Male, n (%) | 10 (50) |
| Living arrangement, n (%) | |
| Living alone | 4 (20) |
| Living with spouse/family | 16 (80) |
| Employment status | |
| Retired | 12 (60) |
| Not working for medical reasons | 4 (20) |
| Working (full or part-time) | 4 (20) |
| Age of asthma diagnosis, mean (SD) | 23.70 (21.59) |
| Asthma Control Questionnaire | 2.05 (1.37) |
| Past year asthma attacks | 4.45 (2.26) |
| Inhaled corticosteroids (Beclomethasone equivalent units), median (IQR) | 2000 (1000, 2000) |
| Maintenance Prednisone, n (%) | 10 (50) |
| Maintenance Prednisone Dose (mg), mean (SD) | 29.45 (38.16) |
| Novel medication*, n (%) | |
| Azithromycin | 5 (25) |
| Mepolizumab | 15 (75) |
| Omalizumab | 5 (25) |
| Duration of Monoclonal antibody therapy (months), median (IQR) | 12.50 (7.00, 24.00) |
Note: *Azithromycin was an add-on therapy to the monoclonal medications.